Hsin-Yu Chen1,2, Shih-Hsiang Ou1,2, Chien-Wei Huang1,2, Po-Tsang Lee1,2, Kang-Ju Chou1,2, Pei-Chin Lin3,4, Yi-Chia Su5,6. 1. Division of Nephrology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. 2. School of Medicine, National Yang-Ming University, Taipei, Taiwan. 3. Department of Medical Education and Research, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung, 813, Taiwan. 4. Department of Pharmacy, School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan. 5. Department of Pharmacy, Kaohsiung Veterans General Hospital, 386 Ta-Chung 1st Road, Kaohsiung, 813, Taiwan. pauleoswu@hotmail.com. 6. Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng-Kung University, Tainan, Taiwan. pauleoswu@hotmail.com.
Abstract
BACKGROUND AND OBJECTIVE: Systematic reviews and meta-analyses of direct oral anticoagulants (DOACs) for patients with chronic kidney disease (CKD) or dialysis patients are lacking. We aimed to compare the efficacy and safety of DOACs and warfarin in patients with CKD requiring anticoagulation therapy. METHODS: We performed a systematic review and meta-analysis of six randomized controlled trials and 19 observational studies, with the inclusion criteria being a comparative study between DOACs and warfarin in patients with CKD or dialysis patients from database inception until August 2020. The efficacy outcomes were stroke, systemic embolism (SE), or venous thromboembolism (VTE), and the safety outcome was major bleeding. RESULTS: Compared with warfarin, DOACs significantly reduced the risk of stroke/SE/VTE by 22% (hazard ratio [HR] = 0.78, 95% confidence interval [CI] 0.64-0.95) and major bleeding by 17% (HR = 0.83, 95% CI 0.71-0.97). On comparing factor Xa inhibitors and dabigatran with warfarin separately, factor Xa inhibitors significantly reduced the risk of stroke/SE/VTE (HR = 0.78, 95% CI 0.62-0.98) and major bleeding (HR = 0.76, 95% CI 0.64-0.91) overall in patients. Comparing each DOACs with warfarin separately, apixaban was associated with a significantly better risk reduction of stroke/SE/VTE (25% risk reduction) and major bleeding (35% risk reduction) than warfarin. Compared with warfarin, DOACs significantly reduced the risk of stroke, SE, or VTE by 19% (HR = 0.81, 95% CI 0.68-0.97) in patients with CKD stage 3 and significantly lowered the risk of major bleeding by 31% (HR = 0.69, 95% CI 0.56-0.85) in patients with CKD stages 4-5. CONCLUSIONS: In pooled, analyzed randomized controlled trials and observational studies, DOACs were associated with better efficacy in early CKD, as well as similar efficacy and safety outcomes to warfarin in patients with CKD stages 4-5 or dialysis patients. The results of patients with CKD stages 4-5 and dialysis patients were from observational studies. Well-designed randomized controlled trials focused on DOAC use in patients with CKD and dialysis patients are needed. PROSPERO register number: CRD42020150599, 6 February, 2020.
BACKGROUND AND OBJECTIVE: Systematic reviews and meta-analyses of direct oral anticoagulants (DOACs) for patients with chronic kidney disease (CKD) or dialysis patients are lacking. We aimed to compare the efficacy and safety of DOACs and warfarin in patients with CKD requiring anticoagulation therapy. METHODS: We performed a systematic review and meta-analysis of six randomized controlled trials and 19 observational studies, with the inclusion criteria being a comparative study between DOACs and warfarin in patients with CKD or dialysis patients from database inception until August 2020. The efficacy outcomes were stroke, systemic embolism (SE), or venous thromboembolism (VTE), and the safety outcome was major bleeding. RESULTS: Compared with warfarin, DOACs significantly reduced the risk of stroke/SE/VTE by 22% (hazard ratio [HR] = 0.78, 95% confidence interval [CI] 0.64-0.95) and major bleeding by 17% (HR = 0.83, 95% CI 0.71-0.97). On comparing factor Xa inhibitors and dabigatran with warfarin separately, factor Xa inhibitors significantly reduced the risk of stroke/SE/VTE (HR = 0.78, 95% CI 0.62-0.98) and major bleeding (HR = 0.76, 95% CI 0.64-0.91) overall in patients. Comparing each DOACs with warfarin separately, apixaban was associated with a significantly better risk reduction of stroke/SE/VTE (25% risk reduction) and major bleeding (35% risk reduction) than warfarin. Compared with warfarin, DOACs significantly reduced the risk of stroke, SE, or VTE by 19% (HR = 0.81, 95% CI 0.68-0.97) in patients with CKD stage 3 and significantly lowered the risk of major bleeding by 31% (HR = 0.69, 95% CI 0.56-0.85) in patients with CKD stages 4-5. CONCLUSIONS: In pooled, analyzed randomized controlled trials and observational studies, DOACs were associated with better efficacy in early CKD, as well as similar efficacy and safety outcomes to warfarin in patients with CKD stages 4-5 or dialysis patients. The results of patients with CKD stages 4-5 and dialysis patients were from observational studies. Well-designed randomized controlled trials focused on DOAC use in patients with CKD and dialysis patients are needed. PROSPERO register number: CRD42020150599, 6 February, 2020.
Authors: Usman Baber; Virginia J Howard; Jonathan L Halperin; Elsayed Z Soliman; Xiao Zhang; William McClellan; David G Warnock; Paul Muntner Journal: Circ Arrhythm Electrophysiol Date: 2010-11-13
Authors: James B Wetmore; Jonathan D Mahnken; Sally K Rigler; Edward F Ellerbeck; Purna Mukhopadhyay; John A Spertus; Qingjiang Hou; Theresa I Shireman Journal: Kidney Int Date: 2011-12-21 Impact factor: 10.612
Authors: Jonas Bjerring Olesen; Gregory Y H Lip; Anne-Lise Kamper; Kristine Hommel; Lars Køber; Deirdre A Lane; Jesper Lindhardsen; Gunnar Hilmar Gislason; Christian Torp-Pedersen Journal: N Engl J Med Date: 2012-08-16 Impact factor: 91.245
Authors: Elsayed Z Soliman; Ronald J Prineas; Alan S Go; Dawei Xie; James P Lash; Mahboob Rahman; Akinlolu Ojo; Val L Teal; Nancy G Jensvold; Nancy L Robinson; Daniel L Dries; Lydia Bazzano; Emile R Mohler; Jackson T Wright; Harold I Feldman Journal: Am Heart J Date: 2010-06 Impact factor: 4.749
Authors: Wanwarat Ananthapanyasut; Sirikarn Napan; Earl H Rudolph; Tasma Harindhanavudhi; Husam Ayash; Kelly E Guglielmi; Edgar V Lerma Journal: Clin J Am Soc Nephrol Date: 2009-12-10 Impact factor: 8.237
Authors: Marco Proietti; Marina Camera; Maurizio Gallieni; Luigi Gianturco; Antonio Gidaro; Carlo Piemontese; Giuseppe Pizzetti; Franco Redaelli; Barbara Scimeca; Carlo Sebastiano Tadeo; Matteo Cesari; Giuseppe Bellelli; Laura Adelaide Dalla Vecchia Journal: J Pers Med Date: 2022-03-15